Development of a Neuronal Viability Assay Using SH-SY5Y Cells
Ryan J. Bujol1, Daniel E. Oseid2 and Anne S. Robinson1,3
1Department of Chemistry, Spring Hill College, 4000 Dauphin St., Mobile, AL 36608
2Neuroscience Program, Tulane University, 2007 Percival Stern, New Orleans, LA 70118
3Department of Chemical and Biomolecular Engineering, Tulane University 2007 Percival Stern, New Orleans, LA 70118

Abstract
Alzheimer’s disease affects more than 35 million people internationally and accounts for 50-70% of all dementia cases1,2. This is a compounding problem as the general population is aging and living longer. There are many potential causes of dementia, but one of the most striking is neuronal cell death. Viability assays are an important scientific tool that allows one to compare the toxicity of harmful substances of interest by a standard of cell death using precise conditions and measurement techniques. Here, a viability assay was created using the human neuroblastoma cell line, SH-SH5Y, and increasing concentrations of hydrogen peroxide (H2O2) were used to elicit cell stress and cytotoxicity. Neurotoxicity was measured using flow cytometry in combination with a proprietary live/dead dye. Previously, phosphorylated tau protein oligomers have been shown to be neurotoxic, and possibly be one of the steps that is responsible for eliciting dementia and potentially Alzheimer’s3. Good et al. has shown that Aβ oligomers are neurotoxic to cultured SH-SY5Ys4. This work will provide assistance for future experiments in which a pure tau sample can be obtained and assayed for cytotoxicity.

Flow Cytometry
Figure 2. The effect of hyperphosphorylated tau on neurons. Tau protein functions to stabilize microtubules normally, but when tau becomes hyperphosphorylated, it tends to fall off and form oligomers. This destabilizes microtubules, inhibits cellular transport, and decreases neuronal polarity. Furthermore, tau oligomers can be neurotoxic.

SH-SY5Y Cells

Viability Assay

Figure 3. The basics of flow cytometry. A suspension of cells is brought up by the machine and passed through a laser in a single-file line. The light is scattered as it passes through the cell, and based on the direction and intensity, the cytometer can determine relative size, complexity, and fluorescence if available. A major advantage to flow cytometry is obtaining quantifiable data.

Figure 4. Overlaid histograms representing the flow cytometry data from a viability assay using a live/dead assay dye obtained from Enzo Life Sciences. The Enzo dye contains a green fluorescent dye that is excluded by live cells and included by dead cells. Viability assays were done by first seeding a 6-well plate with undifferentiated SH-SY5Y cells. Once these cells adhered to the wells, they were differentiated with 10µM retinoic acid and allowed to grow for another 2 days, changing media whenever necessary. After differentiation, stress media consisting of 0, 100, 200, 400, and 800 µM H2O2 were applied to the different wells and incubated for 2 hours. After incubation, the Enzo dye was applied in phosphate buffered saline (PBS), and then incubated for 30 minutes. After this, the wells were scraped and resuspended in PBS before being analyzed in the flow cytometer.

Future Work
• Obtain pure tau samples and develop a method to promote oligomerization
• Perform a viability assay on differentiated SH-SY5Y cells similar to the one described in this experiment
• Compare flow cytometry data from stress viabilities to oligomerized tau viabilities
• Correlate tau and stress concentrations to cell death in order to attain a relative neurotoxicity of tau oligomers

Acknowledgements
• This material is based upon work supported by the National Science Foundation under the NSF EPSCoR Cooperative Agreement No. EP-1003879 with additional support from the Louisiana Board of Regents.
• Thank you to the entire Robinson lab for all their help and support.

References
2) Dementia Fact Sheet N°362. (2015)
3) Dementia Fact Sheet N°362:329-344
5) Figure 2. Tau in healthy neurons and in tauopathies. Reprinted from Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies by Brunold, K., Trojanowski, J., and Lee, V., 2009, Nature Reviews Drug Discovery, 8:783-793
6) Flow Cytometry Diagram Picture. flowcytometry.med.uab.edu.ca